BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27549509)

  • 61. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
    Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of thoracic radiotherapy timing and duration on progression-free survival in limited-stage small cell lung cancer.
    Zhao S; Zhou T; Ma S; Zhao Y; Zhan J; Fang W; Yang Y; Hou X; Zhang Z; Chen G; Zhang Y; Huang Y; Zhang L
    Cancer Med; 2018 Sep; 7(9):4208-4216. PubMed ID: 30019533
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
    Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
    J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mid-course thoracic radiotherapy with cisplatin-etoposide chemotherapy in limited-stage small-cell lung cancer.
    Akyurek S; Onal C; Cagar A; Hicsonmez A; Andrieu MN; Kurtman C
    Med Oncol; 2006; 23(4):499-505. PubMed ID: 17303908
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
    Reymen B; Van Loon J; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1319-24. PubMed ID: 23200174
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Concurrent versus sequential chemotherapy and radiotherapy in limited disease small cell lung cancer: a retrospective comparative study.
    El Sharouni SY; Kal HB; Barten-Van Rijbroek A; Struikmans H; Battermann JJ; Schramel FM
    Anticancer Res; 2009 Dec; 29(12):5219-24. PubMed ID: 20044639
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
    Valan CD; Slagsvold JE; Halvorsen TO; Herje M; Bremnes RM; Brunsvig PF; Brustugun OT; Fløtten Ø; Levin N; Sundstrøm SH; Grønberg BH
    Anticancer Res; 2018 Feb; 38(2):871-876. PubMed ID: 29374714
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
    Grønberg BH; Killingberg KT; Fløtten Ø; Brustugun OT; Hornslien K; Madebo T; Langer SW; Schytte T; Nyman J; Risum S; Tsakonas G; Engleson J; Halvorsen TO
    Lancet Oncol; 2021 Mar; 22(3):321-331. PubMed ID: 33662285
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
    Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
    J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
    Komaki R; Paulus R; Ettinger DS; Videtic GM; Bradley JD; Glisson BS; Langer CJ; Sause WT; Curran WJ; Choy H
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e531-6. PubMed ID: 22560543
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.
    Li C; Xiong Y; Zhou Z; Peng Y; Huang H; Xu M; Kang H; Peng B; Wang D; Yang X
    Med Oncol; 2014 Dec; 31(12):369. PubMed ID: 25416052
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
    Han J; Fu C; Li B
    Radiat Oncol; 2021 Mar; 16(1):47. PubMed ID: 33663551
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
    Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer.
    An C; Jing W; Zhang Y; Liu S; Wang H; Zhu K; Kong L; Guo H; Zhu H
    Future Oncol; 2017 Jun; 13(13):1149-1158. PubMed ID: 28326834
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Accelerated hypofractionated thoracic radiotherapy in limited disease small cell lung cancer : comparison with the results of conventionally fractionated radiotherapy.
    Socha J; Guzowska A; Tyc-Szczepaniak D; Wierzchowski M; Sprawka A; Szczesna A; Kepka L
    J BUON; 2015; 20(1):146-57. PubMed ID: 25778310
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The impact of radiation dose and fractionation on outcomes for limited-stage small-cell lung cancer.
    Tomita N; Kodaira T; Hida T; Tachibana H; Nakamura T; Nakahara R; Inokuchi H
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1121-6. PubMed ID: 19665321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.